NZ717159A - A delayed release drug formulation - Google Patents

A delayed release drug formulation

Info

Publication number
NZ717159A
NZ717159A NZ717159A NZ71715913A NZ717159A NZ 717159 A NZ717159 A NZ 717159A NZ 717159 A NZ717159 A NZ 717159A NZ 71715913 A NZ71715913 A NZ 71715913A NZ 717159 A NZ717159 A NZ 717159A
Authority
NZ
New Zealand
Prior art keywords
delayed release
polymeric material
soluble polymeric
inner layer
layer comprises
Prior art date
Application number
NZ717159A
Other languages
English (en)
Inventor
González Roberto Carlos Bravo
Thomas Buser
Felipe José Oliveira Varum
Abdul Waseh Basit
Ana Cristina Freire
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Priority to NZ747731A priority Critical patent/NZ747731A/en
Publication of NZ717159A publication Critical patent/NZ717159A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ717159A 2013-10-29 2013-10-29 A delayed release drug formulation NZ717159A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ747731A NZ747731A (en) 2013-10-29 2013-10-29 A delayed release drug formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/072648 WO2015062640A1 (en) 2013-10-29 2013-10-29 A delayed release drug formulation

Publications (1)

Publication Number Publication Date
NZ717159A true NZ717159A (en) 2019-06-28

Family

ID=49515360

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ747731A NZ747731A (en) 2013-10-29 2013-10-29 A delayed release drug formulation
NZ717159A NZ717159A (en) 2013-10-29 2013-10-29 A delayed release drug formulation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ747731A NZ747731A (en) 2013-10-29 2013-10-29 A delayed release drug formulation

Country Status (25)

Country Link
US (1) US10799515B2 (OSRAM)
EP (2) EP3542791A1 (OSRAM)
JP (1) JP6273356B2 (OSRAM)
KR (2) KR102237356B1 (OSRAM)
CN (2) CN105555260B (OSRAM)
AU (2) AU2013404367B2 (OSRAM)
BR (2) BR122020013726B1 (OSRAM)
CA (1) CA2923063C (OSRAM)
CR (1) CR20160192A (OSRAM)
CU (1) CU20160055A7 (OSRAM)
EA (1) EA032504B1 (OSRAM)
HK (1) HK1222547A1 (OSRAM)
IL (2) IL244260B (OSRAM)
MA (1) MA38847B2 (OSRAM)
MX (2) MX388063B (OSRAM)
MY (1) MY189394A (OSRAM)
NZ (2) NZ747731A (OSRAM)
PH (2) PH12020551522A1 (OSRAM)
SA (2) SA114360006B1 (OSRAM)
SG (1) SG11201600501UA (OSRAM)
TN (1) TN2016000119A1 (OSRAM)
TW (3) TWI736031B (OSRAM)
UA (1) UA117260C2 (OSRAM)
WO (1) WO2015062640A1 (OSRAM)
ZA (1) ZA201600630B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800095T1 (it) * 2012-04-30 2018-03-08 Tillotts Pharma Ag Formulazione di farmaco a rilascio ritardato
EP4119539A1 (en) 2015-09-23 2023-01-18 XWPharma Ltd. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
RU2020123390A (ru) * 2017-12-21 2022-01-21 Пепсико, Инк. Одноразовая капсула напитка с несколькими ингредиентами для приготовления напитка
EP3662898A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
ES2994844T3 (en) * 2018-12-07 2025-02-03 Tillotts Pharma Ag Colonic drug delivery formulation
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662901B1 (en) * 2018-12-07 2025-01-01 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
GB201906917D0 (en) * 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions
CN114786652A (zh) * 2019-12-11 2022-07-22 赢创运营有限公司 用于治疗或预防疾病的剂型

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
FR2711525B1 (fr) * 1993-10-29 1996-01-12 Virbac Laboratoires Forme Galénique à administration orale pour animaux, son procédé de préparation et ses applications.
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
CA2236605A1 (en) 1997-05-09 1998-11-09 Yves Duccini Scale inhibitors
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
ES2198872T3 (es) 1999-12-16 2004-02-01 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. Preparaciones farmaceuticas multiunitarias gastrorresistentes que contienen piroxicam.
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
FI20000780L (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
US20030035839A1 (en) 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
WO2002096405A1 (en) * 2001-05-25 2002-12-05 Ssp Co., Ltd. Drug preparations
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
EP1560597A4 (en) 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED GENES INVOLVED IN CANCER, POLYPEPTIDES CODED THEREWITH, AND METHODS OF USING GENES
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2004058228A1 (en) 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US9161918B2 (en) * 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US20100285123A1 (en) 2005-06-20 2010-11-11 Rudresha Korlakunte Virupakshalah Prasad Controlled Release Dosage Formulation of Duloxetine
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
JP2008214249A (ja) * 2007-03-02 2008-09-18 Takeda Chem Ind Ltd 製剤における溶出改善方法および溶出性の改善された製剤
EP2143424A4 (en) 2007-03-26 2013-07-31 Teikoku Seiyaku Kk ORAL PHARMACEUTICAL PREPARATION FOR SPECIFIC DELIVERY TO THE COLON
AU2007352872B2 (en) 2007-05-07 2013-03-14 Evonik Operations Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
US20090162434A1 (en) 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
US20110177164A1 (en) 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
CA3129996C (en) 2009-06-15 2025-09-02 Amarin Pharmaceuticals Ireland Limited COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISED LDL-C LEVELS IN A SUBJECT UNDERGOING CONCOMITANT STATIN THERAPY
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
WO2011049309A2 (ko) 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
EP2384746A3 (en) * 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
US20130259947A1 (en) 2010-11-29 2013-10-03 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
WO2013035081A2 (de) 2011-09-07 2013-03-14 JÄNISCH, Melisa Optimale formulierung zur freisetzung eines wirkstoffes im dickdarm
CN102319218B (zh) * 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
SMT201800095T1 (it) 2012-04-30 2018-03-08 Tillotts Pharma Ag Formulazione di farmaco a rilascio ritardato
US9844436B2 (en) 2012-10-26 2017-12-19 Edwards Lifesciences Corporation Aortic valve and conduit graft implant tool

Also Published As

Publication number Publication date
IL244260B (en) 2021-08-31
SA116370660B1 (ar) 2019-02-24
MX2016001840A (es) 2016-08-11
EP3062776A1 (en) 2016-09-07
IL244260A0 (en) 2016-04-21
MA38847A1 (fr) 2017-08-31
CA2923063C (en) 2021-09-07
MY189394A (en) 2022-02-09
CN110279669A (zh) 2019-09-27
PH12016500307A1 (en) 2016-05-16
KR20200075041A (ko) 2020-06-25
TN2016000119A1 (en) 2017-10-06
KR20160077040A (ko) 2016-07-01
BR112016004863A8 (pt) 2020-02-11
SA114360006B1 (ar) 2016-11-09
KR102237356B1 (ko) 2021-04-08
EP3542791A1 (en) 2019-09-25
AU2013404367A1 (en) 2016-02-18
UA117260C2 (uk) 2018-07-10
AU2020201365A1 (en) 2020-03-12
CR20160192A (es) 2016-07-13
TW201944984A (zh) 2019-12-01
US10799515B2 (en) 2020-10-13
MA38847B2 (fr) 2021-02-26
SG11201600501UA (en) 2016-02-26
TWI736031B (zh) 2021-08-11
CN105555260A (zh) 2016-05-04
KR102174942B1 (ko) 2020-11-06
CN105555260B (zh) 2021-04-23
IL265381B (en) 2022-05-01
MX388063B (es) 2025-03-19
TWI680774B (zh) 2020-01-01
HK1222547A1 (zh) 2017-07-07
WO2015062640A1 (en) 2015-05-07
BR122020013726B1 (pt) 2022-11-01
PH12020551522A1 (en) 2022-11-14
CA2923063A1 (en) 2015-05-07
MX2019002162A (es) 2019-06-17
TW201542243A (zh) 2015-11-16
BR112016004863B1 (pt) 2022-09-20
TWI725458B (zh) 2021-04-21
EA032504B1 (ru) 2019-06-28
JP2016535030A (ja) 2016-11-10
US20160250232A1 (en) 2016-09-01
EA201690596A1 (ru) 2016-08-31
NZ747731A (en) 2020-02-28
JP6273356B2 (ja) 2018-01-31
IL265381A (en) 2019-05-30
ZA201600630B (en) 2017-05-31
PH12016500307B1 (en) 2022-02-11
AU2020201365B2 (en) 2021-09-16
AU2013404367B2 (en) 2020-02-27
CU20160055A7 (es) 2016-10-28
MX382146B (es) 2025-03-13
CN110279669B (zh) 2022-02-15
TW202011945A (zh) 2020-04-01

Similar Documents

Publication Publication Date Title
PH12016500307A1 (en) A delayed release drug formulation
JOP20200148B1 (ar) تركيبة عقار ذو إطلاق متأخر
PH12017502369A1 (en) A delayed release drug formulation
GEP20207119B (en) A delayed release drug formulation
TH148827A (th) สูตรผสมยาชนิดปลดปล่อยแบบชะลอ
PE20160211A1 (es) Formulacion de farmaco de liberacion retardada

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 OCT 2020 BY CPA GLOBAL

Effective date: 20191026

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 OCT 2021 BY CPA GLOBAL

Effective date: 20200917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 OCT 2022 BY CPA GLOBAL

Effective date: 20210916

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 OCT 2023 BY CPA GLOBAL

Effective date: 20220915

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 OCT 2024 BY CPA GLOBAL

Effective date: 20230914

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240912

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 OCT 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250911